SCHEMBL8193371

SCHEMBL8193371

O=C1C[C@H](COC(=O)c2ccccc2)[C@@H](COC(=O)c2ccccc2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.53
PPM1B O75688 1/20 0.52
TDP1 Q9NUW8 2/20 0.50
CHRNB2 P17787 1/20 0.49
CHRNA5 P30532 1/20 0.49
CHRNA7 P36544 1/20 0.49
CHRNA4 P43681 1/20 0.49
KMT2A Q03164 2/20 0.49
MAPK1 P28482 1/20 0.49
HIF1A Q16665 1/20 0.49
SLC6A2 P23975 1/20 0.49
SLC6A3 Q01959 1/20 0.49
LMNA P02545 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TSHR P16473 1/20 0.45
FOLH1 Q04609 1/20 0.45
NPC1 O15118 1/20 0.45
MEN1 O00255 1/20 0.44
ATM Q13315 1/20 0.44
F2 P00734 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3727933 0.86 TDP1 (0.50) CES2PPM1BTDP1CHRNB2CHRNA5
SCHEMBL13286850 0.84 PPM1B (0.56) CES2PPM1BTDP1CHRNB2CHRNA5
SCHEMBL11323408 0.84 CES2 (0.46) CES2PPM1BTDP1CHRNB2CHRNA5
SCHEMBL2447975 0.82 CES2 (0.56) CES2PPM1BTDP1CHRNB2CHRNA5
SCHEMBL2447972 0.82 CES2 (0.56) CES2PPM1BTDP1CHRNB2CHRNA5
SCHEMBL7705887 0.82 CES2 (0.56) CES2PPM1BTDP1CHRNB2CHRNA5
SCHEMBL2447976 0.82 CES2 (0.56) CES2PPM1BTDP1CHRNB2CHRNA5
SCHEMBL9310364 0.81 TDP1 (0.52) CES2PPM1BTDP1CHRNB2CHRNA5
SCHEMBL15046638 0.80 CHRNB2 (0.50) CES2PPM1BTDP1CHRNB2CHRNA5
SCHEMBL29413708 0.79 CES2 (0.46) CES2PPM1BTDP1CHRNB2CHRNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6121431-A VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS B VIRUS MEDIVIR AB (SE) 2000-09-19 US disclosed
US-5952500-A VIRICIDES CAN BE USED IN THERAPEUTIC AND PROPHYLACTIC TREATMENT OF THE ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS), INFECTIONS OF HUMAN IMMUNE DEFICIENCY VIRUSES, HEPATITIS B VIRUS, HERPES VIRUSES AND CANCER MEDIVIR AB (SE) 1999-09-14 US disclosed
US-5747473-A L-nucleoside analogues and pharmaceutical compositions MEDIVIR AB (SE) 1998-05-05 US disclosed
US-5473063-A Reacting 2,3-epoxy-butanediol/1,4-/(having protected hydroxyl groups) with an alpha allylic nucleophile yields 2-hydroxy-3-allyl-1,4-butanediol, then oxidatively cleaving the double bond, cyclization, halogenation, acetylation or oxyalkylation MEDIVIR AB (SE) 1995-12-05 US disclosed
EP-0554274-A1 NUCLEOSIDE DERIVATIVES Medivir Aktiebolag (SE) 1993-08-11 EP disclosed
WO-1992006102-A1 NUCLEOSIDE DERIVATIVES MEDIVIR AB (SE) 1992-04-16 WO disclosed